Brent Sabatini Sells 7,711 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) CAO Brent Sabatini sold 7,711 shares of the business’s stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $9.12, for a total transaction of $70,324.32. Following the completion of the sale, the chief accounting officer directly owned 61,902 shares in the company, valued at $564,546.24. This trade represents a 11.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Brent Sabatini also recently made the following trade(s):

• On Tuesday, February 24th, Brent Sabatini sold 1,430 shares of Vir Biotechnology stock. The stock was sold at an average price of $9.53, for a total transaction of $13,627.90.
• On Monday, February 23rd, Brent Sabatini sold 1,829 shares of Vir Biotechnology stock. The shares were sold at an average price of $7.45, for a total transaction of $13,626.05.
• On Friday, February 13th, Brent Sabatini sold 1,530 shares of Vir Biotechnology stock. The shares were sold at an average price of $7.79, for a total value of $11,918.70.

Vir Biotechnology Stock Down 0.3%

NASDAQ:VIR opened at $8.96 on Friday. Vir Biotechnology, Inc. has a 52 week low of $4.16 and a 52 week high of $10.94. The stock’s fifty day moving average is $8.26 and its two-hundred day moving average is $6.68. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -2.84 and a beta of 1.65.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings data on Monday, February 23rd. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.11. The business had revenue of $64.07 million during the quarter, compared to analysts’ expectations of $19.91 million. Vir Biotechnology had a negative return on equity of 49.31% and a negative net margin of 638.88%.The company’s revenue was up 417.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.76) earnings per share. On average, sell-side analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Barclays lifted their target price on Vir Biotechnology from $26.00 to $30.00 and gave the company an “overweight” rating in a research report on Tuesday, February 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Monday, December 22nd. Evercore restated an “outperform” rating and issued a $18.00 price objective on shares of Vir Biotechnology in a report on Tuesday, February 24th. Needham & Company LLC upped their target price on shares of Vir Biotechnology from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday, February 24th. Finally, HC Wainwright increased their target price on shares of Vir Biotechnology from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Vir Biotechnology presently has an average rating of “Moderate Buy” and an average price target of $20.44.

Institutional Investors Weigh In On Vir Biotechnology

Large investors have recently bought and sold shares of the stock. Rockefeller Capital Management L.P. raised its position in Vir Biotechnology by 187.3% in the 4th quarter. Rockefeller Capital Management L.P. now owns 29,869 shares of the company’s stock valued at $180,000 after purchasing an additional 19,472 shares in the last quarter. Corient Private Wealth LLC grew its position in shares of Vir Biotechnology by 1.0% during the fourth quarter. Corient Private Wealth LLC now owns 262,211 shares of the company’s stock worth $1,572,000 after buying an additional 2,515 shares in the last quarter. Virtus Investment Advisers LLC increased its stake in shares of Vir Biotechnology by 82.4% during the fourth quarter. Virtus Investment Advisers LLC now owns 39,764 shares of the company’s stock worth $240,000 after buying an additional 17,966 shares during the period. Tudor Investment Corp ET AL purchased a new stake in shares of Vir Biotechnology during the fourth quarter worth approximately $414,000. Finally, Polymer Capital Management US LLC acquired a new stake in Vir Biotechnology in the fourth quarter valued at approximately $202,000. Hedge funds and other institutional investors own 65.32% of the company’s stock.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.